Exagen, Inc. XGN

Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow. Key Investor TakeawaysExagen (NASDAQ:XGN) reported record second-quarter revenue of $19.

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates. Three Months Ended June 30, Six Months Ended June 30, 202

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46th Annual Growth Conference – Boston, MADate: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen’s Investor Relations website at investors.exagen.com. About Exagen Inc.Exagen Inc. (Nasdaq: XGN) is a leadin

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company’s results. Conference Call and Webcast: U.S. dial-in: 877-407

Exagen is back in focus as analysts refresh their price targets, with the latest models continuing to anchor around an unchanged US$8.67 fair value estimate. Recent Street commentary links these trimmed targets to updated assumptions about valuation, execution risk and the company’s potential growth path, even as the core dollar-based output holds steady. As you read on, you will see how to track these shifts and what to watch as the Exagen story continues to evolve. Stay updated as the Fair...

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced t

Exagen Inc (XGN) reports a 12% revenue increase and reaffirms its full-year guidance, despite facing operational hurdles and financial challenges.